Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 4/20 | 0.35 |
| ▸ | THRB | P10828 | 4/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393109 | 0.88 | ESR1 (0.53) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL6440111 | 0.82 | ESR1 (0.44) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL3396365 | 0.82 | NPSR1 (0.52) | ESR1ESR2ARVDRRORC | |
| SCHEMBL13672861 | 0.80 | HDAC3 (0.37) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL13366680 | 0.77 | HDAC3 (0.43) | HDAC3HDAC6VDRPKMHPGD | |
| SCHEMBL13786217 | 0.77 | HDAC6 (0.54) | ARHDAC3HDAC6VDR | |
| SCHEMBL13366813 | 0.76 | HDAC3 (0.49) | ARHDAC3HDAC6VDR | |
| SCHEMBL13366689 | 0.76 | ESR1 (0.48) | ESR1HDAC3HDAC6VDR | |
| SCHEMBL3391173 | 0.75 | HDAC3 (0.58) | ESR1ARHDAC3HDAC6VDR | |
| SCHEMBL3388734 | 0.75 | HDAC6 (0.45) | HDAC3HDAC6VDRHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184281-A1 | Phenyl-thiophene type vitamin D receptor modulators | Eli Lilly & Company (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1511740-B1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20060287536-A1 | Phenyl-thiophene type vitamin d receptor modulators | ELI LILLY AND COMPANY | 2006-12-21 | — | — | US | disclosed |
| US-20060135484-A1 | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators | ELI LILLY AND COMPANY PATENT DIVISON (US) | 2006-06-22 | — | — | US | disclosed |
| EP-1587905-A3 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1587905-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1511740-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004063348-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003101978-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135484-A1 | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | ESR1 377/4885ESR2 280/4885AR 208/4885 |
| US-20060287536-A1 | Phenyl-thiophene type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | ESR1 180/4885ESR2 167/4885AR 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.